Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 228 participants.

Also called NCT07552389

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 228 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07552389
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07552389. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-18 (actual); primary completion 2028-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus
Condition
Hypertension
Condition
Diabete Type 2
Intervention (Drug)
Test group
Intervention (Drug)
Exploratory test group
Intervention (Drug)
Control group 1
Intervention (Drug)
Control group 2
Lead sponsor
Hanlim Pharm. Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07552389
Content hash
424a995397d59353de0aff1a0bdeeb8208937fbdaf4ba3ad52a53a883f3e4ccd